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Abstract 
Red blood cell transfusion (RBCT) threshold in patients with sepsis remains a matter of controversy. A threshold of  
7 g/dL for stabilized patients with sepsis is commonly proposed, although debated. The aim of the study was to 
compare the benefit and harm of restrictive versus liberal RBCT strategies in order to guide physicians on RBCT strate‑
gies in patients with severe sepsis or septic shock. Four outcomes were assessed: death, nosocomial infection (NI), 
acute lung injury (ALI) and acute kidney injury (AKI). Studies assessing RBCT strategies or RBCT impact on outcome 
and including intensive care unit (ICU) patients with sepsis were assessed. Two systematic reviews were achieved: 
first for the randomized controlled studies (RCTs) and second for the observational studies. MEDLINE, EMBASE, Web 
of Science Core Collection, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews 
and Clinical Trials.gov were analyzed up to March 01, 2015. Der Simonian and Laird random‑effects models were 
used to report pooled odds ratios (ORs). Subgroup analyses and meta‑regressions were performed to explore studies 
heterogeneity. One RCT was finally included. The restrictive RBCT strategy was not associated with harm or benefit 
compared to liberal strategy. Twelve cohort studies were included, of which nine focused on mortality rate. RBCT 
was not associated with increased mortality rate (overall pooled OR was 1.10 [0.75, 1.60]; I2 = 57%, p = 0.03), but was 
associated with the occurrence of NI (2 studies: pooled OR 1.25 [1.04–1.50]; I2 = 0%, p = 0.97), the occurrence of ALI (1 
study: OR 2.75 [1.22–6.37]; p = 0.016) and the occurrence of AKI (1 study: OR 5.22 [2.1–15.8]; p = 0.001). Because there 
was only one RCT, the final meta‑analyses were only based on the cohort studies. As a result, the safety of a RBCT 
restrictive strategy was confirmed, although only one study specifically focused on ICU patients with sepsis. Then, 
RBCT was not associated with increased mortality rate, but was associated with increased in occurrence of NI, ALI and 
AKI. Nevertheless, the data on RBCT in patients with sepsis are sparse and the high heterogeneity between studies 
prevents from drawing any definitive conclusions.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Anemia is frequent in intensive care medicine and is 
associated with increased morbidity and worsened out-
come [1]. In severe sepsis and septic shock patients, the 
red blood cell transfusion (RBCT) threshold remains 
controversial. Indeed, RBCT may improve oxygen deliv-
ery into tissues and is one of the main interventions of 
the early goal-directed therapy (EGDT) [2]. Conse-
quently, for many years, a 10 g/dL hemoglobin level has 
been recommended during the early phase of septic 
shock. Nonetheless, adverse events such as overload, 
infectious complications and immunomodulatory effects 
of transfusion have been described [3–5]. Therefore, low-
ering the transfusion threshold might reduce the volume 
of transfusion in patients and may prove beneficial [6]. 
Indeed, a restrictive transfusion strategy has been recom-
mended and acknowledged for most of the non-septic 
patients but is still not fully established for ICU patients 
with sepsis [7, 8].
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As a result, two main questions remain open regard-
ing septic patients: first, what is the optimal transfusion 
threshold, and second, does transfusion impact on clini-
cally relevant outcomes, including mortality, and occur-
rence and/or duration of organ failure. In that context, 
several studies specifically focused on septic ICU patients 
were recently conducted. For instance, a randomized 
controlled trial (RCT) published in 2014 [9] showed that 
lowering the transfusion threshold was not harmful for 
patients with septic shock. Then, several observational 
studies have been recently published with controversial 
results regarding the impact of transfusion on mortality 
[10–13]. Until now, no systematic review has specifically 
focused on the impact of transfusion neither on the out-
come nor on the transfusion thresholds for septic ICU 
patients. In this context, the purpose of this study was to 
perform a systematic review and meta-analysis regarding 
transfusion among critically ill adults with sepsis in order 
to address these two questions: (1) what are the benefits 
or harms of restrictive transfusion strategies compared to 
liberal ones, and (2) what is the impact of transfusion on 
septic critically ill patients with regard to their mortality, 




This review was systematic and comprised two subcat-
egories: (1) RCTs dealing with the comparison of two 
transfusion thresholds; and (2) observational studies on 
the impact of transfusion on the outcome among ICU 
patients with sepsis. The preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) guide-
lines statement [14] was followed for the randomized 
controlled trials, and the meta-analysis of observa-
tional studies in epidemiology (MOOSE) guidelines [15] 
applied for the observational studies.
The research question was formulated according to 
the participants, interventions, comparisons and out-
comes (PICO) model as follows: P, septic ICU adults; 
I, red blood cell transfusion for the observational stud-
ies and restrictive strategy for the RCTs; C, no transfu-
sion for the observational studies and liberal strategy 
for the RCTs and O, all the outcomes were considered, 
such as death, nosocomial infection, occurrence of acute 
lung injury, except outcomes (events) collected during 
the first week after ICU admission. As a result, we only 
selected studies which included ICU patients with severe 
sepsis or septic shock, and that assessed the effects of 
RBCT on outcome for observational studies and that 
compared two transfusion thresholds (restricted versus 
liberal strategies) for the RCTs. Relative risk (RR), odds 
ratio (OR), hazard ratio (HR) or standardized incidence/
mortality ratio (SIR/SMR) with their specific 95% confi-
dence intervals (CIs) had to be reported or were calcu-
lated from the article. We only focused on English- and 
French-written articles published between the January 
01, 1995, and the December 31, 2014. The main search 
was performed in November 2014 and updated in 
March 2015. We did not consider studies in some spe-
cific populations: pediatric patients, trauma patients, 
patients with burns, patients undergoing surgery and 
among them cardiac surgery, and patients with acute 
coronary syndromes or with acute brain injury. We also 
excluded studies that assessed the benefice of a system-
atic leukoreduction versus a non-leukoreduction of the 
packed RBC, and studies evaluating the effects of red cell 
storage duration. Research sources included MEDLINE, 
central, Web of Science Core Collection, Cochrane Cen-
tral Register of Controlled Trials, Cochrane Database of 
Systematic Reviews and ClinicalTrials.gov. Search terms 
were “sepsis,” “septic shock,” “transfusion,” “intensive 
care,” “threshold,” “cohort,” “randomized trials,” “out-
come.” Boolean algorithms with specific terms were 
elaborated for each of the two subcategories of studies. 
They are listed in Additional file 1.
Study selection
Study selection was conducted through independent 
review. Two independent reviewers (C.D. and J.F.T.) 
examined abstracts for eligibility. In case of disagreement 
based on abstract, the full-text article was obtained to 
determine the study eligibility. All duplicated studies or 
studies that only described methods of the trials without 
reporting results or studies with ineligible comparison or 
inadequate outcome were excluded.
Data extraction and quality assessment
A data extraction form was developed prior to articles 
review, enabling to record the first author’s last name, 
publication year, period of inclusion, country, study 
design, inclusion criteria, number of participating sites, 
number of participating patients, proportion of patients 
with sepsis, probability of death at admission extrapo-
lated from the severity score at ICU admission, statisti-
cal methods and covariates used for adjustment, patients’ 
outcome(s) and risk estimates with their 95% confidence 
intervals. From the randomized trials, we collected 
hemoglobin thresholds, number of participating patients 
and main results. Data extraction was conducted inde-
pendently by two investigators, with subsequent dis-
cussion and resolution of discrepancies by consensus. 
In case of missing data, we contacted the authors of the 
original studies.
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Meta‑analysis
Effects estimates were primarily presented as adjusted 
odds ratios (ORs). Unadjusted ORs were used in the 
absence of adjusted OR. Because of the high prevalence of 
the events, OR could not be approximated by the hazard 
ratios (HRs) [16]. As a result, if the studies only reported 
HR, data were used to calculate non-adjusted odds ratios 
that were used into the meta-analysis. We pooled indi-
vidual study data using Der Simonian–Laird proportion 
methods. Due to anticipated heterogeneity, we used a 
random-effects meta-analysis, which considered both 
within-study and between-study variations. Heterogene-
ity was assessed using I2 statistics, Chi-square test, Tau2 
and by visualization in a funnel plot. For the Q statistic, a 
p value of less than 0.10 was used as an indication of the 
presence of heterogeneity; for I2, a value >50% was con-
sidered a measure of severe heterogeneity. To explore 
potential heterogeneity between studies, several subgroup 
analyses were conducted, first with statistical strate-
gies and then in accordance with the different outcomes. 
Then, meta-regressions were performed with the first year 
of inclusions and the estimated patients’ severity of illness 
at admission as covariates. Sensitivity analyses were con-
ducted based on extraction of potential outliers.
Publication bias was evaluated using a funnel plot of 
a trial’s effect size against the standard error. All statis-
tical analyses were performed using RevMAn, version 
5.3 (Nordic Cochrane Centre, Cochrane Collaboration, 
Copenhagen, Denmark), except for the meta-regression 
which was performed with the package metaphor with 
the “R” software (version 2.13.0 R Foundation for Sta-
tistical Computing, Vienna, Austria). A two-tailed p 
value of less than 0.05 was considered to be statistically 
significant.
Quality assessment and risk of bias across the studies
To assess the quality of the randomized controlled stud-
ies, the risk of bias tool was used [17]. As far as observa-
tional studies are concerned, most of the quality scoring 
remained controversial with lack of validity. Neverthe-
less, we decided to use a modified version of the New-
castle–Ottawa quality assessment scale [18]. The item 
concerning control group was not taken into account 
because all controls and cases were extracted from the 
same database. In the case of prospective digital cohort, 
the ascertainment of cohort and patients’ outcomes 
could be considered of high quality and thus associated 
with a low risk of bias. On the opposite, a high risk of 
bias was attributed to retrospective data collection from 
manual records or administrative databases. The follow-
up periods of all studies were long enough. If more than 
20 percent of the data were missing, we considered the 
risk of bias as high.
Results
Search results
Two main analyses were thus conducted. The first one 
focused on randomized controlled trials comparing 
restrictive versus liberal transfusion strategies and the 
second one on cohort studies.
Description of the RCT
One hundred and thirteen articles were identified after 
consultation of the different databases. Among them, 103 
were assessed based on title and abstract and 10 assessed 
on full-text articles. Finally, only one study was included, 
conducted by Holst [9] (Fig. 1). The solely eligible study 
concluded that none of the strategies was associated 
with an increased 90-day mortality (RR 0.94 [0.78–1.09], 
p = 0.4). In the restrictive strategy group, patients were 
less transfused [unit transfused during ICU stay: 1 [0–3] 
versus 4 [2–7], and proportion of patients free of trans-
fusion during ICU stay: 176 (36.1%) vs. 6 (1.2%)]. How-
ever, protocol violations were more frequent in the 
restrictive group than in the liberal one (5.9 vs. 2.2%, 
p = 0.004) because of ischemic events or acute bleeding 
most of the time. Summaries of this study and its qual-
ity assessment are reported in Table 1 and in Additional 
file 2: Tables S1 and S2. Of note, in a post hoc analysis, a 
meta-analysis of the randomized controlled trials of ICU 
patients that included septic and non-septic patients and 
compared restrictive versus liberal strategies (3 studies), 
was achieved and did not reveal differences in the risk 
of mortality (RR 0.81 [0.63–1.04] [I2 =  41%, p =  0.18)] 
(Additional file 2: Figure S2) [6, 9, 19].
Description of the cohort studies
Our search strategy identified 312 studies for potential 
inclusion. Among them, only 250 were eligible based on 
abstract’s assessment. Then 187 were excluded because 
they were not observational studies, or conducted within 
an inappropriate cohort (no ICU patients with sepsis), or 
outcome (outcomes collected during the first week after 
ICU admission). Among the 63 remaining studies, 12 
were finally included into our systematic review (Fig. 2). 
In these studies, the main outcome parameter analyzed 
was death (8 studies), acute lung injury (1 study), acute 
kidney injury (1 study) and nosocomial infections (2 stud-
ies). The characteristics of the studies are summarized in 
Table 1 and Additional file 2: Table S3. The selected arti-
cles were actually published between 2005 and 2014, and 
inclusions were conducted between 1998 and 2013.
With respect to the study quality assessment, the num-
ber of missing values was not reported in 55% of the stud-
ies, and no confounding factors were taken into account 
in around 15% of the studies. As a result, six studies could 
be categorized as low risk of bias. Summaries of the 
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quality assessment are reported in Figs.  3 and 4 and in 
Additional file 2: Table S4 and Figure S1.
Death
Two of the nine studies with death as outcome were 
excluded from the meta-analysis due to missing crude 
and/or adjusted odds ratios [20, 21]. As a result, 2762 
patients from 7 studies were included. The median year 
of publication was 2012 (2012–2012). All inclusions 
started after 2000. Five studies started before 2010 and 2 
after. Four of the studies were multicentric studies; three 
were prospectively conducted. The median population 
size was 285 [189–476], and the probability of death at 
admission was 42.4 [35.95–51.8]. Multivariate logistic 
regression models were used in five studies, Cox mod-
els in one study and univariate analyses in one study. The 
endpoints considered were hospital mortality (3 studies), 
death at day 28 (3 studies) and death at day 90 (1 study).
The crude pooled odds ratio (OR) was 1.1 [0.75–1.60] 
(I2  =  57%, p  =  0.03). Among all included studies, the 
study of Park [13] was the only one to report a protec-
tive effect of the transfusion and was thus considered as 
an outlier. This study differed from the others on differ-
ent points: First, it was the largest study included into 
our meta-analysis; second, only 62.3% of the patients 
included were in septic shock with the lowest probabil-
ity of death at admission (27.3%); third, the hemoglobin 
before transfusion was one of the lowest ever reported in 
Fig. 1 Flow diagram of search strategy for the randomized controlled trials (RCTs)
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the literature (Hb = 7.7 g/dL). Then, it was the only study 
in which a Cox model on a propensity matching cohort 
was used. The meta-analysis was rerun without the 
study of Park, and the pooled OR was 1.32 [1.01–1.74] 
(I2 =  0%, p =  0.73). Subgroups analyses and univariate 
meta-regressions were achieved to explore heterogeneity 
(Fig. 5). Then, considering the various statistical models, 
the pooled OR of the univariate analyses was 0.78 [0.3–
2.03] (I2  =  73%, p  =  0.05); the one of the multivariate 
analyses was 1.32 [0.99–1.76] (I2 = 0%, p = 0.59). Of note, 
the study which used a Cox model [13, 22, 23] had an HR 
of 0.43 [0.29–0.62]; p  <  0.001 (Fig.  6). All the subgroup 
analyses and sensitivity analyses are reported in Fig.  7. 
Then, in the meta-regression, neither the year of the first 
Fig. 2 Flow diagram of search strategy for the cohort studies
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inclusions (I2 = 55.0%, p = 0.03) nor the risk of death at 
admission (I2 = 55.0%, p = 0.03) was associated with the 
outcome, and none of them could explain heterogeneity. 
Publication bias was not obvious through the inspection 
of the funnel plot (data not shown).
Nosocomial infections
Two studies dealt with nosocomial infections [24, 25]. 
The first one [25] started in 1998, was retrospective, 
monocentric, with an univariate analysis and included 
only 73 patients; whereas the second one [24] started in 
2004, contained a multivariate analysis and included 134 
patients. Their pooled OR was 1.25 [1.04–1.5] (I2 = 0%, 
p = 0.97).
Acute lung injury (ALI)
Only the prospective cohort of Iscimen [26] assessed the 
occurrence of ALI among 162 ICU patients with sepsis; 
it showed a deleterious effect of transfusion (OR 2.75 
[1.22–6.37]; p = 0.016).
Acute kidney injury (AKI)
Only the study of Plataki [27] assessed the occurrence of 
AKI after transfusion among ICU patients with sepsis; it 
demonstrated a deleterious effect of transfusion (OR 5.22 
[2.1–15.8]; p = 0.001).
Discussion
This systematic review suggested that a restrictive strat-
egy could be achieved and that transfusion was not 
associated with increased mortality but rather with the 
occurrence of nosocomial infections, acute lung injuries 
or kidney injuries. Nevertheless, because of the limited 
number of studies on transfusion focusing specifically 
on patients with sepsis, added to the heterogeneity of 
the studies dealing with death, no definitive conclu-
sions should be drawn. All those results deserved several 
comments.
First, the only study focusing specifically on RBCT 
thresholds among patients with septic shock suggested 
the safety of the restrictive strategy [9]. This result is in 
line with the results of two RCTs enrolling both septic 
and non-septic patients and of our post hoc meta-analy-
sis (Additional file 2: Figure S2) [6, 9, 19]. However, some 





































































Fig. 3 Risk of bias summary: quality assessment of the included 
cohort studies, using modified version of the Newcastle–Ottawa 
quality assessment scale











Fig. 4 Risk of bias graph: quality assessments of included cohort studies, using modified version of the Newcastle–Ottawa quality assessment scale
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patients were excluded; therefore, the safety of a restric-
tive strategy during the early phase of septic shock is still 
not explored and further study is needed. In that con-
text, three recent RCTs (ProCESS [28], ARISE [29] and 
ProMISe [30]), included in a meta-analysis from Angus 
[31] concluded that the EGDT described by Rivers [2] 
was no more associated with a better outcome. Fur-
thermore, two cohort studies showed that transfusion 
was safe and even beneficial during this early phase of 
septic shock [32, 33] and underlined that ScVO2 or lac-
tate should be considered to trigger transfusion. Then, 
because of a partial blinding in the available RCT, many 
physicians did not comply with the restrictive strategy in 
case of risk of ischemic events. Similarly, patients with 
ongoing ischemic events were excluded. Consequently, 
the external applicability of the result could not be fully 
guaranteed, specifically concerning septic patients with 
cardiovascular events. Of note, two other studies, one 
after cardiac surgery [34] and another one in onco-hema-
tology [35], were in favor of a liberal RBCT strategy. As 
a result, the real safety of a drastic systematic restric-
tive transfusion threshold among patients with sepsis 
must be addressed and further research is needed to 
determine which patients with sepsis may actually ben-
efit from restrictive transfusion strategies. Several sub-
groups should be thus considered with a special interest 
on older patients, on patients with cardiac comorbidi-
ties, with acute ischemic event, acute brain injury or with 
Fig. 5 Forest plot of odds ratios: impact of red blood cell transfusions on mortality rate; CI confidence interval, IV inverse variance, SE standard error
Fig. 6 Forest plot of odds ratios: impact of red blood cell transfusions on mortality rate; subgroup analyses: statistical modeling. CI confidence 
interval, IV inverse variance, SE standard error
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cancer for whom a Hb threshold of 8–9  g/dL may be 
more appropriate.
Second, from the cohort studies, we demonstrated that 
transfusion did not impact death rate. This result differed 
from those of other studies conducted in ICU patients or 
after myocardial infarctions [36–42] where transfusion 
was deleterious. One explanation could be that patients 
with sepsis increased their basal metabolic and oxygen 
demands and thus could be more beneficial from transfu-
sion [43]. The improvement of microcirculation by trans-
fusion in case of baseline alteration in septic patients has 
also been demonstrated [44]. Nevertheless, the meta-
analysis pointed out the significant heterogeneity of the 
transfusion effect in septic patients. The study from Park 
et  al. [13] that showed a protective effect of transfusion 
was one of the main sources of heterogeneity (Fig. 7). This 
could be explained in part because of a lower transfu-
sion threshold [13] (Hb = 7.7 (1.2) g/dL). Another source 
of heterogeneity was the statistical modeling. Indeed, 
some results were obtained after adjustment, and others 
without any, and only one study took into account time-
dependent covariates by using a Cox model. Of note, the 
impact of deleukocytation could not be explored because 
of not systematically reported (Table 1).
Third, it is quite difficult to reach the real causal effect 
of RBCT because of treatment repetitions and of the 
many baseline- and time-dependent confounding factors. 
Until nowadays, none of the studies published have han-
dled all those issues. Furthermore, it is important to know 
that Cox models with time-dependent covariates might 
also be biased if the proportional hazard assumption was 
not ascertained [45] and also because ICU discharge is an 
informative censor and modifies the risk of mortality and 
morbidity events [46]. Newer statistical causal models 
that can handle repetition of the treatments, such as the 
marginal structural models, should thus be used.
Fourth, our review suggested that transfusion was 
associated with the occurrence of nosocomial infection. 
Those results are in accordance with those of another 
recent meta-analysis [47], which demonstrated that 
restrictive strategies were associated with a reduction 
of the occurrence of healthcare-associated infections. 
Transfusion-related immune modulation (TRIM) should 
be considered as the main explanation [5, 48]. Mecha-
nisms for TRIM include suppression of cytotoxic cells 
and monocyte activity, release of immunosuppressive 
prostaglandins, inhibition of interleukin-2 (IL-2) produc-
tion and increase in suppressor T-cell activity and leu-
kocytes. In this respect, the occurrence of nosocomial 
infections could be minimized thanks to deleukocyta-
tions of the RBCT, as demonstrated by several stud-
ies [49]. However, Jufferman also found an association 
between RBCT and nosocomial infections even after a 
systematic leukodepletion [24]. It could be explained by 
the few remaining leukocytes in RBCT, but also by the 
presence of biological active cytokines or others immu-
nomodulating components of the red blood cells them-
selves. Furthermore, patients with sepsis might be more 
sensitive to the TRIM because of their previous immuno-
suppressive states.
Fifth, transfusion was associated with an increased risk 
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Fig. 7 Analysis of heterogeneity: subgroup analyses: impact of red blood cell transfusion on mortality rate; OR odds ratio; CI confidence interval, IV 
inverse variance
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study, and only few physiologic studies focused on the 
impact of transfusion on kidney function [44]. However, 
some authors believed that transfusion may elicit a renal 
injury similar to lung injury because of immunologic 
mechanisms and of overload [27, 50, 51].
Last, transfusion was associated with acute lung injury. 
From those studies, it was not possible to make the dif-
ference between immunologic mechanisms [transfu-
sion-related acute lung injury (TRALI)] or overload 
[transfusion-associated cardiac overload (TACO)].
Study strengths and limitations
Our study had several strengths. First, it was the first 
meta-analysis to specifically focus on ICU patients with 
sepsis. Second, even if the main part of our analysis 
consisted of a meta-analysis of observational studies, a 
structured approach was used and heterogeneity of the 
results was explored rigorously. Furthermore, risk of bias 
was assessed thanks to an adaptation of the Newcastle–
Ottawa quality assessment scale, an accepted tool for 
cohort studies. Then, the funnel plot did not show any 
study effects and was in favor of a good research strategy.
Our study has, however, several limitations. First, there 
is only one randomized controlled trial. Consequently, 
this review mostly relies on observational studies. Then, 
the heterogeneity could not be fully explored. Indeed, 
several important factors such as leukodepletion, trans-
fusion thresholds or age of the packed RBC could not 
be included into the analyses because they were not suf-
ficiently reported. Third, it was not possible to integrate 
into our meta-analysis the data extracted from the stud-
ies dealing with EGDT. Finally, the two questions raised 
into this study may be quite limited and perhaps a more 
general question such as “how should we treat anemia in 
critically ill septic patients: only according to Hb labora-
tory values or according to anemia tolerance?” could be 
more appropriate. In that context, tolerance of anemia 
and thus transfusion thresholds should be considered 
as time-dependent variables. Furthermore, other treat-
ments including transfusion-saving strategies such as 
administration of iron or erythropoietin in ICU, but also 
other transfusion triggers than Hb level such as lactate, 
ST elevation, ScVO2 or microcirculation should be inte-
grated into the various analyses.
As a conclusion, restrictive RBCT strategies were asso-
ciated with neither benefit nor harm compared to liberal 
strategies, and RBCT did not impact mortality but the 
occurrence of nosocomial infection. Because of sparse 
data and limits of observational studies, additional stud-
ies should be achieved. First, in order to explore the early 
phase of septic shock, a restrictive strategy could be 
assessed with a RCT. Then, because of the limits of RCTs 
in the case of adverse events such as ischemic events, we 
believed that observational studies with newer statisti-
cal causal models would be less biased and could lead to 
more definitive conclusions about the deleterious effect 
of transfusion in different subgroups and for different 
outcomes. Other transfusion triggers than hemoglobin 
should be explored.
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